期刊文献+

小剂量米力农在治疗老年性顽固性心力衰竭患者的临床观察 被引量:10

The Analysis Efficacy and Safety of Taking Small Dose Milrinone in theTreatment of Elderly Patients with Intractable Heart Failure
下载PDF
导出
摘要 目的观察小剂量米力农治疗老年患者顽固性心力衰竭的疗效及安全性。方法将老年顽固性心力衰竭住院患者分为两组,对照组为常规剂量使用米力农,观察组为小剂量使用米力农,分别在治疗前后5d记录心功能、NTproBNP、LVEF、心律、血压的情况。结果两组心功能、NT-proBNP均较用药前有明显改善,有效率分别为93.1%、92%,两组的有效率无差异(P>0.05),EF变化不大;而观察组心律失常及低血压的发生率低于对照组。结论小剂量米力农治疗老年顽固性心力衰竭有效、安全。 Objective To evaluate the efficacy and safety of using small dose milrinone in the treatment of elderly patients with intractable heart failure. Methods The elderly patients with intractable heart failure were divided into two groups. The control group were taken conventional dose milrinone, and the observation group were taken small dose milrinone. The data of heart function, NT-proBNP, LVEF, heart rate, blood pressure were recorded before and after the treatment for 5 days. Results The heart function, pro-BNP of two groups were significantly improved compared with those before treatment, and the effective rate of control group and observation group were 93. 1% and 92% respectively, but the effective rate were not significantly different( P 〉0. 05). EF were not significantly improved. The occurrence rate of arrhythmias and hypotension in the observation group were lower than the control group. Conclusion small dose milrinone should be more effective and safe in the treatment of elderly patients with intractable heart failure.
出处 《四川医学》 CAS 2014年第9期1208-1209,共2页 Sichuan Medical Journal
关键词 米力农 老年 顽固性心力衰竭 心功能 安全性 milrinone old age intractable heart failure heart function security
  • 相关文献

参考文献4

二级参考文献46

  • 1[1]Levy JH, Ramsay J, Bailey JM.Pharmacokinetics and pharmacody namics of phosphodierase- Ⅲ inhibitors.J Cardiothoras Anesth 1990, 4:7- 11
  • 2[2]Monrad ES, McKay RG, Baim DS, et al.Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.Circulation 1984, 70:1030- 1037
  • 3[3]Skoyles JR, Sherry KM.Pharmacology mechanisms of action and uses of selective phosphodiester ase inhibitors.Br J Anaesth, 1992, 68(3):293- 302
  • 4[4]Anderson JL, Baim DS, Fein SA, Goldstein RA, LeJemtel TH, Likeoff MJ.Efficacy and safety of sustained(48 hour)intravenous infusions of milrinone in patients with severe congestive heart failure:a mul- ticenter study.J Am Coll Cardiol, 1987,9:711- 722
  • 5[5]LeJemtel Th, Maskin CS, Chadwick B, Sonnenblick H.HemodEyna- mic effects of intravenouse and oral milrinone in patients with chr- onic heart failure.In Ref,2:133- 142
  • 6[6]Jaski BE, Fifer MA, Wright RF, et al.Positive inotropic and vasodila- tor actions of milrinone in patients with severe congestive heartfailu- re:dose- response relationship and comparison to nitroprusside.J Clin Invest, 1985,75:643- 649
  • 7[7]Bailey JM, Levy JH, Kikura M, et al.Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.Anesthesiology, 1994,81:616- 622
  • 8[8]Akkerm SR, Zhang H, Mullins RE, et al.Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. soluchrns.Am J Health Syst Pharm,1999,56:63- 68
  • 9[9]Braunwald E.Heart failure :evaluation of therapy based on a con sideration of natural history.In:Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz RP Jr, eds.Milrinone:Investigation of New Inotropic Therapy for Congestive Heart Failure.New York:Raven, 1984:1- 13
  • 10[10]Feldman AM, Bristow MR.The β - adrenergic pathway in the failing heart:Implications for inotropic therapy.Cardiology, 1990,77(Suppl 1):1- 32

共引文献38

同被引文献69

  • 1刘霄岩.米力农治疗难治性心力衰竭80例临床观察[J].山东大学学报(医学版),2014,52(S02):61-61. 被引量:3
  • 2邵华,袁高辉.小剂量米力农联合大剂量参麦注射液对扩张型心肌病顽固性心衰的治疗观察[J].基层医学论坛,2007,11(6):492-493. 被引量:3
  • 3陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 4Quirós-Ganga PL,Remón-Rodríguez C,Tejuca-Marenco M,et al.Peritoneal dialysis allows successful cardiac transplantation in patients with refractory heart failure[J].Nefrologia,2015;35(1):121-4.
  • 5Anguita M,Comin J,Almenar L,et al.Comments on the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012[J].Rev Esp Cardiol(Engl Ed),2012;65(10):874-8.
  • 6Shigeru M,Fujiwara S,Takamine S,et al.Predicting the response to cardiac resynchronization therapy using 99m Tc-tetrofosmin myocardial scintigraphy in patients with drug-refractory heart failure:additional value of the washout of 99m Tc-tetrofosmin[J].Nucl Med Commun,2014;35(9):939-46.
  • 7Albrecht CA,Giesler GM,Kar B,et al.Intravenous milrinone infusion improves congestive heart failure caused by diastolic dysfunction[J].Tex Heart Inst J,2015,32(23):220-223.
  • 8Cusick DA,Pfeifer PB,Quigg RJ.Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure[J].Am J Cardiol,2013,82(9):1060-1065.
  • 9Shigeru M, Fujiwara S, Takamine S, et al. Predicting the response to cardiac resynchronization therapy using 99mTc-tetrofosmin myocardial scintigraphy in patients with drug-refractory heart failure: additional value of the washout of 99mTc-tetrofosmin [ J]. Nucl Med Commun, 2014,35 (9) :939-946.
  • 10Quiros-Ganga PL, Remon-Rodriguez C, Tejuca-Marenco M, et al. Peritoneal dialysis allows successful cardiac transplantation in patients with refractory heart failure [ J]. Nefrologia, 2015,35 (1): 121-124.

引证文献10

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部